Arbutus Biopharma Confirms Nasdaq Listing for ABUS Common Shares

Ticker: ABUS · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1447028

Arbutus Biopharma Corp 8-K Filing Summary
FieldDetail
CompanyArbutus Biopharma Corp (ABUS)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: corporate-governance, regulatory-filing, exchange-listing

TL;DR

**ABUS confirms Nasdaq listing, business as usual.**

AI Summary

Arbutus Biopharma Corporation filed an 8-K on January 8, 2024, to report on its current status, including its registration of Common Shares, without par value, under the trading symbol ABUS on The Nasdaq Stock Market LLC. This filing primarily serves to update administrative and registration details, confirming the company's continued listing and compliance. For investors, this matters because it reaffirms Arbutus's presence on a major exchange, ensuring liquidity and transparency for its stock, ABUS.

Why It Matters

This filing confirms Arbutus Biopharma's continued compliance and listing on The Nasdaq Stock Market LLC, which is crucial for maintaining investor confidence and stock liquidity.

Risk Assessment

Risk Level: low — This 8-K is an administrative filing confirming existing information, posing minimal new risk to investors.

Analyst Insight

A smart investor would note this administrative filing confirms ongoing compliance and listing, but it doesn't contain new financial or operational news to directly impact investment decisions. It's a routine check-in.

Key Players & Entities

  • Arbutus Biopharma Corporation (company) — the registrant filing the 8-K
  • ABUS (company) — trading symbol for Arbutus Biopharma's Common Shares
  • The Nasdaq Stock Market LLC (company) — exchange where Arbutus Biopharma's Common Shares are registered
  • January 8, 2024 (date) — date of earliest event reported and filing date

FAQ

What is the purpose of Arbutus Biopharma Corporation's 8-K filing dated January 8, 2024?

The 8-K filing by Arbutus Biopharma Corporation on January 8, 2024, is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, primarily updating administrative information and confirming the registration of its Common Shares on The Nasdaq Stock Market LLC.

What is the trading symbol for Arbutus Biopharma Corporation's common shares?

The trading symbol for Arbutus Biopharma Corporation's Common Shares, without par value, is ABUS, as stated in the filing under 'Securities registered pursuant to Section 12(b) of the Act'.

On which exchange are Arbutus Biopharma Corporation's common shares registered?

Arbutus Biopharma Corporation's Common Shares are registered on The Nasdaq Stock Market LLC, according to the 'Name of each exchange on which registered' section of the filing.

What is the address of Arbutus Biopharma Corporation's principal executive offices?

The address of Arbutus Biopharma Corporation's Principal Executive Offices is 701 Veterans Circle, Warminster, Pennsylvania 18974, as listed in the filing.

What is the Commission File Number for Arbutus Biopharma Corporation?

The Commission File Number for Arbutus Biopharma Corporation is 001-34949, as indicated in the filing.

Filing Stats: 616 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-01-08 07:31:16

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On January 8, 2024, Arbutus Biopharma Corporation (the "Company") issued a press release (the "Press Release") announcing its 2024 corporate objectives and provided certain estimated and projected financial information, including its estimated cash, cash equivalents and investments as of December 31, 2023. The amounts included in the Press Release are preliminary, have not been audited and are subject to change upon completion of the Company's audited financial statements for the year ended December 31, 2023. Additional information and disclosures would be required for a more complete understanding of the Company's financial position and results of operations as of December 31, 2023. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein. On January 8, 2024, the Company posted an updated corporate presentation on its website at www.arbutusbio.com (the "Corporate Presentation"), which included the Company's estimated cash, cash equivalents and investments as of December 31, 2023. A copy of the Corporate Presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.

01. Other Events

Item 8.01. Other Events. On January 8, 2024, the Company issued the Press Release, a copy of which is filed herewith as Exhibit 99.1 hereto and is incorporated by reference herein. A copy of the Corporate Presentation is filed herewith as Exhibit 99.2 hereto and is incorporated by reference herein.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press release dated January 8, 2024 99.2 Corporate Presentation January 8, 2024 104 Cover page interactive data file (formatted as inline XBRL). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Arbutus Biopharma Corporation Date: January 8, 2024 By: /s/ David C. Hastings David C. Hastings Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.